11:45 AM EDT, 06/02/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Monday it presented phase 3 results from its Rosella trial at the American Society of Clinical Oncology annual meeting, showing that its investigational drug relacorilant, combined with nab-paclitaxel, improved outcomes for patients with platinum-resistant ovarian cancer.

The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to chemotherapy alone, with median PFS rising to 6.5 months versus 5.5 months, the company said. An interim analysis also showed a 31% reduction in the risk of death, with overall survival extending to 16 months from 11.5 months.

The combination therapy was well-tolerated, with no increase in serious side effects. Patients on relacorilant had fewer complications such as ascites and abdominal paracenteses during treatment, Corcept Therapeutics ( CORT ) said.

The global trial enrolled 381 patients across the U.S., Europe, South Korea, Brazil, Argentina, Canada and Australia, the company said.

Shares of Corcept were up more than 7% in recent trading.

Price: 83.62, Change: +6.05, Percent Change: +7.81